esophageal cancer
Conditions
Interventions
18F-misonidazole Duration: two days dose: 7.4Mbq/kg
Sponsors
Institute of Advanced Clinical Medicine, Kindai University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patient age less than 80 years old (2)Squamous cell carcinoma patient undergoing FDG-PET/CT before and after NAC (2 course of docetaxel, cisplatin, 5-flurouracil ; DCF) and surgical resection in our institution. (3)Performance status (ECOG) : 0-1
Exclusion criteria
Exclusion criteria: (1) Not received informed consent (2) Patient age less than 20 years old and more than 80 years old (3) Non-squamous cell carcinoma (4) Patient with synchronous cancer (5) Patient undergoing endoscopic mucosal resection (6) Patient undergoing chemoradiotherpy (7) Pregnant woman, lactating woman, possibility of pregnancy (8) Patient with serous complication affecting examination (9) inappropriate patient for this examination justified by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We investigate the diagnostic accuracy of pretreatment FMISO PET/CT to histopathologic response and Positron Emission Tomography (PET) Response Criteria in Solid Tumors. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)We investigate whether pretreatment FMISO PET/CT reflect tumor hypoxia or tumor immunity environment. (2)We investigate the relationship between pretreatment FMISO PET/CT and relapse-free survival (RFS). | — |
Countries
Japan
Contacts
Public ContactHayato Kaida
Institute of Advanced Clinical Medicine, Kindai University Division of Positron Emission Tomography
Outcome results
None listed